Abeysekera, IrushiThomas, JaredGeorgiadis, Taxiarchis M.Berman, Alycia G.Hammond, Max A.Dria, Karl J.Wallace, Joseph M.Roper, Randall J.2017-09-272017-09-272016-04Abeysekera, I., Thomas, J., Georgiadis, T. M., Berman, A. G., Hammond, M. A., Dria, K. J., … Roper, R. J. (2016). Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model. Molecular Nutrition & Food Research, 60(4), 717–726. http://doi.org/10.1002/mnfr.2015007811613-4133https://hdl.handle.net/1805/14186SCOPE: Down syndrome (DS), caused by trisomy of human chromosome 21 (Hsa21), is characterized by a spectrum of phenotypes including skeletal abnormalities. The Ts65Dn DS mouse model exhibits similar skeletal phenotypes as humans with DS. DYRK1A, a kinase encoded on Hsa21, has been linked to deficiencies in bone homeostasis in DS mice and individuals with DS. Treatment with Epigallocatechin-3-gallate (EGCG), a known inhibitor of Dyrk1a, improves some skeletal abnormalities associated with DS in mice. EGCG supplements are widely available but the effectiveness of different EGCG-containing supplements has not been well studied. METHODS AND RESULTS: Six commercially available supplements containing EGCG were analyzed, and two of these supplements were compared with pure EGCG for their impact on skeletal deficits in a DS mouse model. The results demonstrate differential effects of commercial supplements on correcting skeletal abnormalities in Ts65Dn mice. Different EGCG-containing supplements display differences in degradation, polyphenol content, and effects on trisomic bone. CONCLUSION: This work suggests that the dose of EGCG and composition of EGCG-containing supplements may be important in correcting skeletal deficits associated with DS. Careful analyses of these parameters may lead to a better understanding of how to improve skeletal and other deficits that impair individuals with DS.en-USPublisher PolicyBone and Bonesdrug effectsCatechinanalogs & derivativesDown SyndromephysiopathologyDifferential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse modelArticle